
|Articles|September 1, 2006
- Volume 0 0
FDA WARNS AGAINST COMPOUNDING LYME DRUG
Advertisement
The FDA has called on pharmacists tostop compounding a treatment for Lymedisease that has been linked to at leastone patient death and a number of suspectedillnesses. The drug, called bismacineor chromocine, is mixed individuallyby pharmacists for use by injectionto treat the symptoms of the tick-bornebacterial disease. According to the FDA, the substancecontains high amounts of the heavy metal bismuth and isunapproved for use by humans. Agency officials said thatthe substance is sometimes prescribed by "alternativehealth doctors."
Articles in this issue
about 20 years ago
Pharmacy Technology Productsabout 20 years ago
Tobacco Useabout 20 years ago
Rx Product Newsabout 20 years ago
OTC Product Newsabout 20 years ago
can you READ theseRxs?about 20 years ago
Generic Times Product Newsabout 20 years ago
compoundingHOTLINEabout 20 years ago
Compounding for Pediatric Patientsabout 20 years ago
Vaccinations: Current Research and Perceptionsabout 20 years ago
Police and Drug TestingAdvertisement
Related to this article

Peer Reviewed
Semaglutide-Associated Sensory Skin Disturbance in Patients Without Diabetes Treated for Weight Loss
This case series describes 2 instances of cutaneous sensory disturbance during semaglutide therapy in patients without diabetes and discusses possible mechanisms as hypotheses requiring further investigation.

Pharmacists can help identify uncontrolled risk factors, review medications, and reinforce when patients should seek emergency care.

OCEANIC-STROKE supports a potential additional antithrombotic approach for select patients after noncardioembolic stroke or high-risk TIA.

Garlic has a long history in traditional medicine, but evidence for its benefits varies by preparation, and patients taking medications that increase bleeding risk should use it with caution.

The costs to patients, their families, their workplaces, and their communities go well beyond dollars and cents.
Advertisement
Advertisement
Trending on Pharmacy Times
1
Structured Blood Glucose Testing: Why Timing Matters
2
Dexmedetomidine Receives FDA Approval for Acute Treatment for Agitation Associated With Schizophrenia
3
Blood Glucose Testing: When Nonadherence Isn't the Real Issue
4
Giredestrant Plus Everolimus Wins FDA Approval in ESR1-Mutated Advanced Breast Cancer
5



